Identification of a Common Lupus Disease-Associated microRNA Expression Pattern in Three Different Murine Models of Lupus by Dai, Rujuan et al.
Identification of a Common Lupus Disease-Associated
microRNA Expression Pattern in Three Different Murine
Models of Lupus
Rujuan Dai
1*, Yan Zhang
2, Deena Khan
1, Bettina Heid
1, David Caudell
1, Oswald Crasta
2, S. Ansar
Ahmed
1*
1Center for Molecular Medicine and Infectious Diseases (CMMID), Department of Biomedical Sciences and Pathology, Virginia-Maryland Regional College of Veterinary
Medicine, Virginia Polytechnic Institute and State University, Blacksburg, Virginia, United States of America, 2Virginia Bioinformatics Institute, Virginia Polytechnic Institute
and State University, Blacksburg, Virginia, United States of America
Abstract
Background: Recent reports have shown that microRNAs (miRNAs) regulate vital immunological processes and have
emerged as key regulators of immune system development and function. Therefore, it is important to determine miRNA
dysregulation and its pathogenic contribution in autoimmune diseases, an aspect not adequately addressed thus far.
Methodology/Principal Findings: In this study, we profiled miRNA expressions in splenic lymphocytes from three murine
lupus models (MRL-lpr, B6-lpr and NZB/WF1) with different genetic background by miRNA microarray assays and Real-time
RT-PCR. Despite the genetic differences among these three lupus stains, a common set of dysregulated miRNAs (miR-182-
96-183 cluster, miR-31, and miR-155) was identified in splenocytes when compared with age-matched control mice. The
association of these miRNAs with the disease was highlighted by our observation that this miRNA expression pattern was
evident in NZB/W mice only at an age when lupus disease is manifested. Further, we have shown that the miRNA
dysregulation in MRL-lpr mice was not simply due to the activation of splenocytes. By Real-time RT-PCR, we confirmed that
these miRNAs were upregulated in both purified splenic B and T cells from MRL-lpr mice. miR-127 and miR-379, which were
greatly upregulated in splenocytes from lpr mice, were moderately increased in diseased NZB/W mice. In addition, Real-time
RT-PCR revealed that miR-146a, miR-101a, and miR-17-92 were also markedly upregulated in splenic T, but not B cells from
MRL-lpr mice.
Conclusions/Significance: The identification of common lupus disease-associated miRNAs now forms the basis for the
further investigation of the pathogenic contribution of these miRNAs in autoimmune lupus, which will advance our
knowledge of the role of miRNAs in autoimmunity. Given that miRNAs are conserved, with regard to both evolution and
function, our observation of a common lupus disease-associated miRNA expression pattern in murine lupus models is likely
to have significant pathogenic, diagnostic, and/or therapeutic implications in human lupus.
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Introduction
Systemic lupus erythematosus (SLE) is a chronic, complex, and
debilitating systemic autoimmune disease. Patients often face a
lifetime of illness with no effective cures and cope with high
medical care costs. In past decades, the researchers have
extensively focused on the identification of the gene defects in
SLE. While there has been significant progress in the understand-
ing of SLE genetics, which includes mapping of multiple SLE
susceptibility loci/genes in the human and murine genome, to date
no single or combination of structural gene defect has been
identified as a principal pathogenic factor in inducing SLE [1,2,3].
Although genetic factors are important in SLE susceptibility,
attention has now been shifted to the contribution of the epigenetic
regulatory defects including abnormal DNA methylation, histone
modification, and more recently miRNA regulation to lupus
pathogenesis [2].
miRNAs are small (about 22 nucleotides), non-coding RNAs
that regulate gene expression at the post-transcriptional level.
miRNAs usually bind to the 39 untranslated region (39UTR) of
target mRNAs through partial sequence homology, which result in
either translation inhibition or degradation of target message
RNAs (mRNAs). Computational analyses indicate that miRNAs
constitute about 3% of the human genome and regulate at least
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miRNAs have been shown to play essential regulatory roles in a
variety of biological processes including embryogenesis, develop-
ment, cell proliferation and apoptosis, and signaling transduction
[4,5,6]. Importantly, aberrant miRNA expression patterns have
been evident in various pathological conditions, which suggest the
pathogenic roles of miRNA in different human diseases [5,7]. A
flurry of recent reports has documented the critical roles of
miRNAs in regulating immune cell development, fine-tuning
immune responses, and maintaining immune homeostasis
[8,9,10,11]. The involvement of miRNA in immune tolerance
control and autoimmunity has also been suggested by recent
studies in which autoimmunity was induced in mice when miRNA
synthesis was selectively disrupted in regulatory T cells (Treg) or
when miR-17-92 was over expressed in lymphocytes [12,13,14].
Spontaneous genetically lupus-prone murine models including
NZBWF1/J (NZB/W), MRL/MpJ-Fas
lpr/J (MRL-lpr), and con-
genic lupus strain B6.MRL-Fas
lpr/J (B6-lpr) have been extensively
used in numerous published reports and have provided valuable
insight into lupus pathogenesis. These three strains share common
characteristics with regards to the induction of autoantibodies
against dsDNA and other nuclear components, but display
different disease severity, autoantibody profile, and clinical
manifestation, which are caused by the differences in the lupus-
related genetic susceptibility loci and/or the background genome
of these strains [1,3,15]. For example, although B6-lpr mice
produce serum rheumatoid factor and anti-DNA antibodies, they
do not develop obvious glomerulonephritis that is often noticed in
MRL-lpr mice. This observation indicated that Fas gene mutation
(lpr) alone is not sufficient for the development of glomerulone-
phritis. The interaction between lpr gene and MRL background
genome is required for the development of renal disease in MRL-
lpr mice [15,16]. Intriguingly, in the present study, we identify a
miRNA expression pattern in splenic lymphocytes that is common
to all three lupus strains with different genetic background, and
more importantly we demonstrate that this miRNA expression
pattern is associated with lupus disease development.
Results
Identification of a common lupus-associated miRNA
expression pattern in splenic lymphocytes from
genetically lupus-prone mice
To identify a lupus disease-associated miRNA expression
pattern in splenocytes, we performed miRNA microarray assays
to compare the miRNA expression profiles in splenocytes from
three different strains of genetically lupus-prone mice including
MRL-lpr, B6-lpr, and NZB/W mice and their respective control
mice. To maintain uniformity of age, all of the mice were
euthanized at 3-4 months of age. As indicated in figure 1, 49
miRNAs were differentially expressed in MRL-lpr mice when
compared to MRL mice (Fig. 1A); and 24 miRNAs were
differentially expressed in B6-lpr mice when compared to B6
mice (Fig. 1B). Among these dysregulated miRNAs, we noted that
15 miRNAs were common to both lpr strains (Fig. 1C and
Table 1). The permutation test revealed that the possibility of
randomly having an overlap of more than two miRNAs between
dysregulated miRNAs in MRL-lpr and B6-lpr mice is ,0.001.
This indicated that the overlap of 15 dysregulated miRNAs
observed in two lpr strains is significantly above the overlap by
random chance (p,0.001). Interestingly, microarray analysis of
NZB/W and NZW at 3–4 months of age, an age when overt lupus
disease is not evident in NZB/W mice, revealed that only one
miRNA, miR-148a, was significantly upregulated in NZB/W mice
(data not shown).
By Real-time RT-PCR analysis, we confirmed that the
expression levels of miR-182, miR-183, miR-31, miR-127, and
miR-379 were highly upregulated in splenocytes from both of
MRL-lpr and B6-lpr mice when compared to control MRL and
B6 mice, respectively (Fig. 2 A). A report has shown that miR-96 is
clustered with miR-182 and miR-183 in mouse chromosome 6
and is likely generated from the same transcript [17]. Although
microarray assay did not identify the change of miR-96 expression
level in lpr mice, Real-time RT-PCR analysis clearly showed that
miR-96 was markedly upregulated similar to two other members
(miR-182 and miR-183) in the cluster (Fig. 2A).
Given the cell-specific expression of miRNA and divergent roles of
a specific miRNA in different cell types, it is important to determine
the expression of miRNA in purified subsets of splenic lymphoid cells.
Therefore, we also analyzed the expression of miRNAs, which were
altered in whole splenocytes, in purified B cells and T cells from
MRL-lpr and control MRL mice using Real time RT-PCR.
Consistent with the data observed in whole splenocytes, the
expression of miR-182-96-183, miR-31, miR-127 and miR-379
was also significantly increased in purified splenic B cells and T cells
from MRL-lpr mice when compared to MRL mice (Fig. 2B).
Figure 1. miRNA microarray data analysis. (A, B) Heat map
representing the relative miRNA expression levels in splenocytes from
MRL and MRL-lpr (A), and from B6 and B6-lpr mice at 3–4 months of age
(B) (n=4 each group). The miRNAs that demonstrated at least 3-fold
changes with p,0.1, or 2-fold with p,0.05 were selected for
hierarchical cluster analysis to generate the heat map. The color bar
depicts the color contrast level of the heat map. Red and green indicate
high and low expression levels, respectively. (C) Venn diagram
presentation of microarray data.
doi:10.1371/journal.pone.0014302.g001
miRNA Dysregulation in Lupus
PLoS ONE | www.plosone.org 2 December 2010 | Volume 5 | Issue 12 | e14302Selected miRNAs were differentially altered in splenic B
and T lymphocytes from lupus mice
A recent report revealed that miR-146a was decreased in
peripheral blood leukocytes from human lupus patients, which
contributed to the elevation of the type I interferon (IFN) pathway
in human lupus [18]. Other studies have also revealed that miR-
150, miR-155, miR-17-92, and miR-101a play roles in the
regulation of antibody responses, germinal center responses,
inflammatory responses, and/or autoimmunity [7,13,19,20,21].
Considering that miRNA microarray analysis is not as sensitive as
Real-time RT-PCR to detect the alteration of the above-
mentioned miRNAs in lupus mice, we performed Real-time RT-
PCR to analyze the expression of above miRNAs in splenic
lymphocytes. We found that miR-155 and miR-150 were
significantly altered in whole splenocytes, as well as in splenic B
and T cells from MRL-lpr mice when compared to MRL mice
(Fig. 3). The upregulation of miR-155 was also observed in
splenocytes from B6-lpr mice (data not shown). Impressively, we
found that although several members of the miR-17-92 cluster
(miR-17, miR-18a, miR-19a, miR-20a), miR-146a, and miR-101a
were not changed in purified splenic B cells, they were significantly
upregulated in splenic T cells (Fig. 3). However, miR-92, another
member of the miR-17-92 cluster was not changed in either
splenic B or T cells. Overall, our data revealed that the expression
changes in lupus-associated miRNAs such as miR-182-96-183,
miR-31, miR-127, miR-379, miR-155, and miR-150 that were
observed in splenocytes were also evident in purified splenic B and
T cells. However, some miRNAs including miR-17-92 cluster
members, miR-146a and miR-101a were selectively dysregulated
in splenic T cells, but not splenic B cells, suggesting an exclusive
role of these miRNAs in lupus T cells.
The dysregulation of miRNA expression in splenocytes is
associated with lupus disease development
As mentioned earlier, the miRNA changes observed in two lpr
strains were not evident in 3–4 month old NZB/W mice when
compared to age-matched NZW mice. It is important to note that
Table 1. Microarray analysis revealed differentially expressed miRNAs in both MRL-lpr and B6-lpr mice.
MRL-lpr/MRL B6-lpr/B6
miRNA ID p value fold p value fold
Upregulated mmu-miR-127 2.57E-06 6.87 1.86E-03 8.34
mmu-miR-182 9.86E-04 4.08 6.06E-02 4.35
mmu-miR-183 5.65E-06 7.57 5.84E-04 7.71
mmu-miR-300 2.29E-03 2.58 5.64E-02 3.64
mmu-miR-31 2.82E-07 16.22 1.87E-03 9.90
mmu-miR-379 1.02E-07 16.80 7.34E-06 24.37
mmu-miR-382 1.10E-03 3.66 1.90E-02 3.75
mmu-miR-433 1.68E-04 3.48 1.06E-02 4.29
Downregulated mmu-miR-200b 2.76E-02 -2.00 1.18E-02 -5.89
mmu-miR-29b 2.76E-02 -4.76 3.91E-03 -18.28
mmu-miR-29c 4.62E-02 -4.59 2.50E-02 -14.91
mmu-miR-340-5p 1.22E-02 -3.73 7.29E-03 -9.96
mmu-miR-467e 2.57E-06 -13.83 2.71E-02 -4.12
mmu-miR-7a* 4.62E-02 -3.01 4.03E-02 -4.13
mmu-miR-98 7.37E-03 -3.01 9.78E-02 -3.91
doi:10.1371/journal.pone.0014302.t001
Figure 2. Real-time RT-PCR validation of dysregulated miRNA
expression. (A) The graphs show miRNAs that were significantly
upregulated in splenocytes from MRL-lpr and B6-lpr mice when
compared to control MRL and B6 mice, respectively. (B) The graph
shows miRNAs that are upregulated in both purified splenic B and T
cells from MRL-lpr when compared to MRL mice. The graphs represent
the means 6 SEMs (n=4 each). Student t-tests were performed. *, **,
and *** indicate p,0.05, p,0.01, and p,0.001, respectively.
doi:10.1371/journal.pone.0014302.g002
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manifest lupus parameters such as the generation of anti-dsDNA
autoantibodies, an important hallmark of lupus disease. As shown
in figure 4A, the serum anti-dsDNA levels were significantly
increased in MRL-lpr mice and B6-lpr mice when compared to
control MRL and B6 mice, respectively. Nevertheless, these lpr
mice only had moderate mesangial hyperplasia/inflammation in
the glomerulus and did not produce proteinuria (data not shown).
There was no obvious anti-dsDNA production in either NZB/W
or NZW mice at 3–4 months of age (Fig. 4A). Therefore, we
utilized 9-month old NZB/W female mice, which had confirmed
high serum levels of anti-dsDNA autoantibodies (Fig. 4A) and
severe glomerulonephritis and proteinuria (data not shown), to
analyze whether miRNA changes observed in lpr lupus mice are
evident in 9-month old NZB/W mice. To avoid the potential
effect of age on miRNA expression, we also included 9-month old
NZW female mice as controls. Impressively, the expression levels
of miR-182-96-183, miR-31, and miR-155 were markedly
upregulated in 9-month old NZB/W mice when compared to
either 9-month old NZW or 3-4-month old NZB/W mice (Fig. 4B).
miR-127 and miR-379 were also significantly upregulated in 9-
month old NZB/W mice when compared to 3-4-month old NZB/
W. However, the upregulation of miR-127 and miR-379 in 9-
month old NZB/W is not significant when compared to 9-month
old NZW mice (Fig. 4B). These data strongly indicated that the
dysregulation of above miRNAs in splenic lymphocytes is common
in three lupus strains rather than specific to lpr mice.
To further determine whether the changes of lupus-associated
miRNAs are simply a result of activation of lymphocytes in lupus
mice or are associated with the lupus disease development, we
analyzed the expression of selected lupus-associated miRNAs in
freshly-isolated and lipopolysaccharide (LPS)-activated splenocytes
from younger MRL-lpr mice (approx. 1 month-old), an age when
these mice do not develop significant levels of serum anti-dsDNA
autoantibodies. We also included freshly-isolated splenocytes from
3–4 months old MRL-lpr mice, which manifest lupus as positive
controls. As shown in the figure 5, the expression levels of selected
lupus-associated miRNAs including miR-96, miR-31, miR-127,
miR-146a and miR-155 were significantly upregulated in freshly-
isolated splenocytes from 3-4-month old MRL-lpr mice when
compared to 1-month old MRL-lpr mice. This data further
suggested that the upregulation of these miRNAs in lupus mice
was associated with the lupus development. LPS stimulation
significantly increased the expression of miR-146a and miR-155,
which was consistent with the previously published reports in
which miR-146a and miR-155 were shown to be induced by LPS
[22,23]. However, LPS activation did not induce miR-96, miR-31
and miR-127 expression changes in splenocytes. Taken together,
our data strongly indicated that the common changes of miRNAs
in lpr and NZB/W mice are associated with lupus disease
development rather than a simply result of the activation of
lymphocytes in lupus mice.
Discussion
It is becoming apparent that miRNA plays an important role in
immune homeostasis and also in the development or prevention of
autoimmunity. Dysregulated miRNA expression has been evident
in several human autoimmune diseases including multiple sclerosis
(MS), rheumatoid arthritis (RA), and SLE [7,18,24,25,26,27,28].
However, the study of the role of miRNA in autoimmunity is still
in the beginning stage. The precise role of dysregulated miRNAs
as autoimmune disease biomarkers and the function of these
miRNAs in the autoimmune disease process need to be
determined.
Thus far, several reports have revealed abnormal miRNA
expression patterns in peripheral blood mononuclear cell (PBMC)
and renal biopsy samples from human lupus patients, respectively
[18,24,25,29,30]. Intriguingly, it seems that the dysregulated
miRNAs in lupus patients that were determined in one study are
not well reproduced in other studies. For example, the decrease of
miR-146a in PBMC from lupus patient was observed in the study
reported by Tang et al. [18], but not in other published lupus
studies [24,25,29]. The discrepancy of the data from different
human lupus miRNA studies may be due to the difference in the
type of samples, sensitivity of detection methods, and the diversity
in the medical history, disease severity and race of the lupus
patients. Considering that genetic factors contribute significantly
to lupus etiology and may affect miRNA expression, it will be
important to determine a miRNA expression pattern that is
Figure 3. Real-time RT-PCR analysis of selected miRNAs. The expression levels of selected miRNAs were altered specifically in purified splenic
T cells, but not B cells, from MRL-lpr when compared to MRL mice. The graphs represent the means 6 SEMs (n=4 each). Student t-tests were
performed. *, **, and *** indicate p,0.05, p,0.01, and p,0.001, respectively.
doi:10.1371/journal.pone.0014302.g003
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background of patients or animal models.
In this study, we reported a common lupus disease-associated
miRNA expression pattern in three murine lupus models with
different genetic backgrounds. The reported targets and immune
regulatory functions of the lupus disease-associated miRNAs suggest
the potential contribution of these miRNAs to immune tolerance
breakdown and altered B and T lymphocytes function in lupus mice
(Fig. 6).For example, miR-155 has been shown to regulate germinal
center cell responses and generation of high-affinity antibodies by
targeting Pu.1,a ETS familytranscriptionfactor playingcriticalrole
in the development of lymphoid cells [21]. While overexpression of
miR-155 led to the enhanced germinal center responses and
antibody production, depletion of miR-155 inhibited germinal
center responses and reduced the number of memory B cells and
IgG class switched plasma cells [20,21]. Our findings of the up-
regulation miR-155 in splenic B cells may have relevance with the
reported abnormal B cell activation, enhanced germinal center
responses and antibody production in human and murine lupus
[31]. The upregulation of miR-31 in T cells may correlate with the
deficiency of Treg cell development/function in lupus since miR-31
targets Foxp3, a critical transcription factor for Treg cell
development and function [32].
Of particular interest here, we found that miR-182-96-183
cluster is remarkably upregulated in splenic lymphocytes (over 8
folds in lpr mice) from lupus-prone mice. Previous study has shown
that miR-182-96-183 cluster was primarily expressed in the retina,
and rarely detected in the spleen and other tissues from normal B6
mice [17]. Our findings are the first to show that this cluster is
selectively increased in splenocytes from lupus-prone mice, which
may have a potential immune regulatory role in autoimmune
mice. Of particular relevance, the published reports have shown
that miR-182 and miR-96 target transcription factors Foxo1,
Foxo3a, and microphthalmia-associated transcription factor
(MITF), which play critical roles in controlling T and B
lymphocyte homeostasis and tolerance, respectively [33,34,
35,36,37]. T cell-specific deletion of Foxo1 gene in mice led to
spontaneous T cell activation, higher percentage of IFNc, IL-17
secreting CD4
+ T cells, anti-dsDNA autoantibody production, and
tissue inflammation [34]. Inactivation of Foxo3a in mice led to
NF-kB activation, hyperactivation of helper T cell with increased
Th1/Th2 cytokine production and autoimmune inflammation in
salivary gland, lung and kidney [33]. Moreover, inactivation of
MITF in mice induced spontaneous B cell activation and
autoantibody production by suppressing interferon regulatory
transcription factor (IRF)-4, which suggested a role of MITF in
Figure 4. The alteration of miRNAs in splenocytes was related to lupus disease development. (A) The graph shows the serum anti-dsDNA
autoantibody levels in different strains of lupus mice and their respective control mice (n=4 each group). Student t-tests were performed. (B) Real-
time RT-PCR analysis of miRNA expression in splenocytes from NZB/W and NZW mice at 3–4 and 9 months of age, respectively. The graph shows the
means 6 SEMs (n=4 each). One-way ANOVA and the Tukey-Kramer multiple comparisons tests were performed. For both graphs, ‘‘ns’’ denotes non
significant; *, **, and *** indicate p,0.05, p,0.01, and p,0.001, respectively.
doi:10.1371/journal.pone.0014302.g004
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munity [35]. Therefore, the upregulation of miR-96-182-83 in
lupus lymphocytes may cause the decrease of Foxo1/3a and/or
MITF, which in turn leads to the hyperactivation of B and T
lymphocytes, immune tolerance breakdown and development of
autoimmunity. Consistent with this, there is decreased Foxo1
transcript in human SLE and inhibited Foxo3a expression and
activity in MRL-lpr mice ([33,38] and unpublished lab data).
In addition, we found that miR-101a, miR-146a and miR-17-
92 cluster (except miR-92) were upregulated in splenic T cells from
MRL-lpr mice. Further studies will be performed to determine
whether these miRNAs are also altered in splenic T cells from
other murine lupus models. The upregulation of miR-101a is
consistent with the previous finding that miR-101a is upregulated
in CD4
+ T cells from sanroque mice, which develop lupus-like
autoimmune syndrome as a result of loss of Roquin mediated-
repression of the inducible T-cell co-stimulator (ICOS)[39].
Increased miR-17-92 in T cells may lead to T cell tolerance
breakdown in MRL-lpr mice since over expression of miR-17-92
miRNA cluster in lymphocytes promoted lymphocytes prolifera-
tion and induced autoimmunity by targeting Bim and Pten, two
molecules that play critical role in immune tolerance mechanism
[13]. Our finding that miR-146a was significantly upregulated in
splenic T cells from MRL-lpr mice is consistent with recent reports
that have shown miR-146a was increased in splenic CD4
+ T cell
from MRL-lpr mice [40].
In this study, we are the first to report a common dysregulated
miRNA expression pattern in splenocytes from three murine lupus
models with different genetic background. Although we have
shown that the dysregulated miRNAs were associated with the
production of anti-dsDNA autoantibodies and the development of
the lupus, it still needs to be determined whether the dysregulated
expression of these miRNAs are exclusive to lupus (i.e. lupus-
specific). It is plausible that some of these miRNAs may also be
dysregulated in other autoimmune diseases. It is noteworthy that
MRL-lpr and NZB/W mice, in addition to serving as animal
models of human lupus, have also been extensively used as models
of other human autoimmune diseases such as RA or Sjo ¨gren’s
syndrome [41,42]. Therefore, the selected lupus-associated
miRNAs that were determined in these three lupus models may
also play a role in the pathogenesis of RA and/or Sjo ¨gren’s
syndrome. Indeed, miR-146a and miR-155 have been shown
upregulated in PBMC and CD4
+ T cells from human patients
with RA and contributed to RA pathogenesis [43,44].
The identification of a common lupus disease-associated
miRNA expression pattern in splenic lymphocytes from different
lupus-prone mice now forms the basis of the further investigation
to mechanistically understand the pathogenic contribution of these
miRNAs in autoimmune lupus. In figure 6, we outlined the
potential contribution of the common lupus-associated miRNAs to
B and T lymphocyte-mediated lupus pathogenesis based on the
documented role of these miRNAs or their target genes in immune
system. We are currently conducting exhaustive in depth studies to
test these suppositions and to determine the direct contribution of
these miRNAs in lupus pathogenesis. Given that miRNAs are
evolutional conserved and that the murine lupus models used in
Figure 5. The dysregulation of lupus-associated miRNAs in lpr
mice is not simply due to the activation of splenocytes. The
expression levels of selected lupus-associated miRNAs (miR-96, miR-31,
miR-127, miR-146a, and miR-155) in freshly-isolated (MRL-lpr-1 month),
24 hrs of LPS activated (MRL-lpr-1 month-LPS) splenocytes from 1-
month old MRL-lpr mice, and freshly isolated splenocytes from 3-4
month old MRL-lpr mice (MRL-lpr-3-4 months) were analyzed by Real-
time RT-PCR. The graph shows means 6 SEM (n=4 each). ns, non
significant, **, p,0.01, and ***, p,0.001, MRL-lpr-1 month vs. MRL-lpr-1
month-LPS (paired t test), MRL-lpr-1 month vs. MRL-lpr-3/4 months (two
tail t test).
doi:10.1371/journal.pone.0014302.g005
Figure 6. Outline of the potential contribution of the common lupus disease-associated miRNAs to B and T lymphocyte-mediated
lupus pathogenesis.
doi:10.1371/journal.pone.0014302.g006
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believe that these studies will potentially open a new approach for
lupus diagnosis and develop novel strategy for treating of lupus
disease by altering lupus-specific miRNAs in lymphocytes.
Materials and Methods
Ethics
This study has been approved by the Virginia Tech Institutional
Animal Care and Use Committee under Protocol ID #08-124-
CVM.
Mice
Genetically lupus-prone female mice MRL-lpr, NZB/W, B6-
lpr, and their control mice MRL/MpJ (MRL), NZW/LacJ
(NZW), and C57BL/6J (B6) mice were purchased from The
Jackson Laboratory, ME, USA. All mice were housed in the
animal facility at the CMMID, Virginia-Maryland Regional
College of Veterinary Medicine, Virginia Tech. At 3–4 months
of age (a time point when lpr mice develop lupus), MRL-lpr, B6-
lpr, NZB/W and their control mice were euthanized and spleen
tissues were collected to isolate splenocytes. Since NZB/W mice
do not develop fulminant lupus at 3–4 months of age, additional
groups of NZB/W and control NZW mice were euthanized at 9
months of age, when NZB/W develop classic lupus symptoms. In
addition, a group of MRL-lpr mice at 1 month of age, an age
when MRL-lpr mice do not develop significant level of anti-
dsDNA autoantibodies, were also euthanized for the experiment.
Splenocyte preparation, splenic B and T cell purification
Whole splenocytes were isolated using standard procedures
described in detail previously [45,46]. Splenic T cells and B cells
were purified from freshly-isolated splenocytes sequentially using
CD90.2 and CD19 microbeads (Miltenyi Biotec), respectively by
positive selection per the manufacturer’s instruction. The purity of
isolated T cells and B cells was confirmed by flow cytometry after
staining the isolated cells with FITC-conjugated CD90.2 (Thy1.2)
and CD19 antibodies, respectively. For LPS stimulation, the
splenocytes from 1-month old MRL-lpr mice were adjusted to
5610
6 cells/ml, plated in 24-well plate, and then activated for
24 hrs by adding equal volumes of media containing LPS (Sigma,
1000 ng/ml) to seeded cells (final concentration at 500 ng/ml).
miRNA isolation and miRNA Microarray assay
Total RNA, containing miRNA, was isolated from whole
splenocytes and purified splenic B and T cells using mirVana
miRNA isolation kits (Ambion). The total RNA samples from
whole splenocytes were sent to LC Sciences (http://www.
lcsciences.com/) for the microarray assay as we described recently
[47]. A mParaflo microfluidic chip, which included 617 unique,
mature, mouse miRNA, based on the Sanger miRBase Release
12.0, was used for assay. The methods used for microarray data
processing have been described in detail previously [47]. The
miRNAs that demonstrated either at least 3-fold changes with
p,0.1 or at least 2-fold changes with p,0.05 were selected for
generation of the heat map and Venn diagram. The permutation
test was performed to determine that the overlap of the
dysregulated miRNAs observed in MRL-lpr and B6-lpr is a
significant event rather than a random event. Briefly, out of 617
miRNAs on the chip, 400 miRNAs and 347 miRNAs are
detectable in the samples of dataset MRL vs. MRL-lpr and dataset
B6 vs. B6-lpr, respectively. Among them, 49 out of 400 miRNAs
were differentially expressed in MRL-lpr mice when compared to
MRL mice, and 24 out of 347 miRNAs were differentially
expressed in B6-lpr mice when compared to B6 mice. The
permutation test was performed by random sampling of 49
miRNAs from 400 miRNAs that were detectable in dataset of
MRL vs. MRL-lpr and 24 miRNAs from 347 miRNAs that were
detectable in dataset of B6 vs. B6-lpr. The procedure was repeated
for 1000 times to determine the possibility of having an overlap of
miRNAs in the randomly generated datasets.
All the microarray data are MIAME compliant and the raw
data have been deposited in a MIAME compliant database (Gene
Expression Omnibus (GEO)) under the accession number
GSE22359.
Real-time RT-PCR analysis of miRNA expression
As we previously described [47], the Taqman miRNA assay
system (Applied Biosystems) was used to quantify miRNA
expression. The relative expression level of miRNA was
normalized to the endogenous small RNA control, snoRNA 202,
and calculated using the 2
2DDCt (Livak) method.
Analysis of autoimmune parameters
Anti-dsDNA autoantibody ELISA was used to determine serum
anti-dsDNA autoantibody levels as described previously [48].
Briefly, the Nunc MaxiSorp 96 well ELISA plates (Fisher
Scientific) were coated with calf thymus dsDNA (Sigma, 100 mg/
ml) overnight, blocked with PBS-1%BSA, incubated with series
diluted serum samples, and then HRP conjugated goat-anti mouse
IgG-gamma (Sigma). The signal was developed with TMB
substrate (KPL, Inc). The plate was read at 380 nm in a
VersaMax microplate reader (Molecular Devices). Proteinuria
was measured by dipstick analysis using Chemistrip-2GP (Roche).
The kidneys of mice were fixed in buffered formalin and subjected
to histopathological assessment of glomerulonephritis by a
pathologist (Dr. David Caudell) in a blind fashion as previously
reported [49].
Statistical Analysis
All values in the graphs are given as means 6 SEM. To assess
statistical significance, student t-tests or one-way ANOVA and the
Tukey-Kramer multiple comparisons tests were performed using
GraphPad InStat (version 3.0a for Macintosh).
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